Ashvattha Therapeutics reveals promising phase 2 results for migaldendranib, showcasing significant improvements in retinal disease treatment and reduced injection burden.

Financing will fund phase 1b trials evaluating its lead candidate, THN391, for the treatment of Alzheimer’s Disease and Diabetic Macular Edema (DME).

SYL1801 is an investigational siRNA therapy administered via eye drops, rather than intravitreal injection, to treat nAMD.

At ARVO 2025, in Salt Lake City, Utah, Ferhina Ali, MD, MPH, talked about her presentation on the early real-world use of aflibercept 8 mg in treatment-naive patients with neovascular age-related macular degeneration

By making these retinal pigment epithelium (RPE) cells visible, researchers have created implications for early detection of disease and the monitoring of treatment response.

Shifting from a regulatory role to driving innovation directly, Eydelman discusses how the Collaborative Community on Ophthalmic Innovation is reshaping the field, streamlining outdated processes, and advancing patient-centered solutions worldwide.

At ARVO 2025, in Salt Lake City, Utah, C Michael Samson, MD, MBA, gave insight into his data on immune cell profiling in birdshot retinochoroidopathy using single-cell RNA sequencing.

The bill, which passed on May 1, allows for West Virginian ODs to provide certain in-office procedures such as laser treatments

A machine learning model incorporating treated astigmatism and nuanced inputs is advancing the precision and personalization of arcuate keratotomy planning

Rishi Singh, MD, discusses faricimab's real-world effectiveness in treating diabetic macular edema, highlighting improved vision and reduced treatment frequency.

AAVantgarde Bio reveals promising safety and efficacy data for AAV-based therapies targeting Usher syndrome and Stargardt disease at ARVO 2025.

LumiThera's Valeda system offers groundbreaking non-invasive treatment for dry AMD, showing extended vision improvement and safety over 4.5 years.

NCX 470, Nicox’s lead clinical product candidate, is a novel NO-donating bimatoprost eye drop with a dual mechanism of action (nitric oxide and prostaglandin analogue).